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Abstract
The nucleotide-binding and oligomerization domain, leucine-rich
repeat (also known as NOD-like receptors, both abbreviated to
NLR) family of intracellular pathogen recognition receptors are
increasingly being recognized to play a pivotal role in the
pathogenesis of a number of rare monogenic diseases, as well as
some more common polygenic conditions. Bacterial wall con-
stituents and other cellular stressor molecules are recognized by a
range of NLRs, which leads to activation of the innate immune
response and upregulation of key proinflammatory pathways, such
as IL-1β production and translocation of nuclear factor-κB to the
nucleus. These signalling pathways are increasingly being targeted
as potential sites for new therapies. This review discusses the role
played by NLRs in a variety of inflammatory diseases and describes
the remarkable success to date of these therapeutic agents in
treating some of the disorders associated with aberrant NLR
function.
Introduction
Innate immunity plays a critical role in host protection and
employs an array of receptor molecules, including Toll-like
receptors (TLRs), NOD-like receptors (nucleotide-binding
and oligomerization domain, leucine-rich repeat; both abbre-
viated to NLR), retinoic acid-inducible gene-like receptors
and C-type lectin receptors (CLRs). Pathogen recognition
receptors (PRRs), which serve to alert and activate the
defence system, are highly conserved at the molecular level
between yeast ‘stress’ proteins, plants (the resistance [R]
proteins), invertebrates (the Drosophilia Toll molecules) and
vertebrates (Figure 1).
The unexpected finding that the Toll family of proteins share
homology in their signalling domains with the type 1 IL-1
(IL-1β) receptor has considerably improved our under-
standing of IL-1 signalling pathways. This discovery was
drawn from many sources, including Drosophilia develop-
mental genetics, yeast genetics and studies of disease in
plants. The IL-1 family plays an important role in the genesis
of inflammation and host defence, and up to 11 members of
this family have been identified to date [1,2]. Functional roles
have been attributed to five members of this family (IL-1α,
IL-1β, IL-18, IL-1 receptor antagonist and the more recently
reported IL-33). Both IL-1α and IL-1β are proinflammatory
cytokines that are synthesized as precursor molecules, but
the IL-1α precursor, unlike IL-1β, is biologically active. Pro-
IL-1β requires enzymatic cleavage by caspase-1 to be
activated [3,4], which is also true of IL-18 and possibly IL-33 -
the more recently discovered member of IL-1 family.
A series of coordinated interactions between the two major
groups of receptor molecules in the mammalian innate immune
system, the TLRs and NLRs, lead to comprehensive detection
of toxins and ‘stress’ signals at both intracellular and extra-
cellular levels, resulting in a specific response being mounted
against a range of pathogens. The mammalian family of TLRs
is composed primarily of cell-surface receptors, characterized
by the presence of an extracellular leucine-rich repeat (LRR)
motif. The NLRs, which also contain LRR domains, are part of
an intracellular detection system for microbial and danger-
associated molecules from both the extracellular and
intracellular microenvironments. The range of patterns that is
recognized by these molecules is collectively referred to as
pathogen-associated molecular patterns (PAMPs) [5], and
these in turn promote upregulation of co-stimulatory
molecules, with subsequent priming of T cells, and secretion
of inflammatory cytokines by innate immune cells [6-9]. Thus,
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the PRRs provide an effective recognition system for both
PAMPs and damage-associated molecular patterns (DAMPs),
which are a second variety of molecules released as a result
of tissue injury [10].
At this point it is worth noting that an agreed standard
nomenclature for the NLR family is still lacking; in this review
we follow the historic precedent of NLR being defined as
‘NOD-like receptor’, with acknowledgement that the Human
Genome Organization Gene Nomenclature Committee has
proposed the term ‘nucleotide-binding domain, leucine rich
repeat containing family’ as an alternative description for the
NLR abbreviation [11]. However, there remains considerable
inconsistency concerning nomenclature of the NLR group
found in various publications. For instance, NOD1 (nucleotide-
binding oligomerization domain containing 1) may also be
termed NLRC1 (NLR family, CARD domain containing 1), and
NALP1 (NACHT, leucine rich repeat and PYD [pyrin domain]
containing 1) termed NLRP1 (NLR family, pyrin domain
containing 1), and so on.We again refer to the historic
terminology of NOD and NALP throughout, rather than the
proposed Human Genome Organization terminology.
Members of the NLR family share common structural and
functional similarities with the TLRs, which include a carboxyl-
terminal LRR; a central nucleotide binding domain (NACHT)
domain, which has intrinsic ATPase activity; and an amino-
terminal protein-protein interaction domain, which contains
either a caspase activation and recruitment (CARD) domain or
a baculovirus inhibitory repeat domain [12]. The carboxyl-
terminal LRR of the NLRs is responsible for sensing PAMPs,
thereby performing a similar role to that of TLRs. For a
comprehensive description of the tripartite structures of the
NLR family members, agonists and the adaptor molecules, the
reader is referred to the review by Sirad and coworkers [13].
There are two broad functional divisions within the NLRs,
both of which are associated with the presence of large
intracytoplasmic protein complexes; these are the inflamma-
somes, which include the NALP and IL-1β converting enzyme
protease activating factor (Ipaf) inflammasomes, involved in
proinflammatory cytokine production [14], and the Nodo-
somes, which induce antimicrobial effectors such as peptides
and nitric oxide as well as stimulating proinflammatory
signalling and cytokine networks [15]. The inflammasomes all
essentially contain either a NALP or an Ipaf central protein,
plus an adaptor protein, and a caspase recruitment domain
(CARD), which facilitates the activation of caspase-1 or
caspase-5 (Figure 2). The NALP1 inflammasome was the first
such multimeric complex to be described, in 2002 by
Martinon and coworkers [16], when it was found to assemble
as a result of bacterial intracellular stress signals or toxins,
with subsequent caspase-1 and caspase-5 activation.
Previous studies had found an association of the adaptor
protein PYCARD (also termed apoptosis-associated speck-
like protein [ASC], which we use in this review) with IL-1β;
this conversion of pro-IL-1β to its active form required the
activation of caspase-1 [17], but a second stimulus, such as
ATP, nigericin or bacterial toxins, was also required to induce
the formation of the inflammasome, and to enhance the
proteolytic maturation and secretion of IL-1β [18].
IL-1β is involved in the pathogenesis of numerous diseases
with an inflammatory component [19], which is best demon-
strated by the therapeutic benefits of treating these conditions
with IL-1 agonists, such as IL-1 receptor antagonist. These
diseases include hereditary periodic fevers, the prototypic
autoinflammatory syndromes [20,21], which are discussed in
greater detail below.
The inflammasomes
NALP1 inflammasome
To date, 14 NALP proteins have been identified in the mam-
malian host [22], some with undetermined functions. Those
NALPs that have been demonstrated to form inflammasome
complexes (NALP1 and NALP3) play a major role in the
initiation of the innate immune system, as well as priming
adaptive immunity, and are essential for cytosolic detection of
multiple DAMPs and PAMPs (Figure 2).
NALP1 (NLRP1, CARD7, DEFCAP, CLR17.1) was the first
NALP protein to be identified [16,23,24], and after discovery
Figure 1
Species homology between the Toll, TLRs, NLRs and plant resistance
(R) proteins. Central to innate immunity are the highly conserved core
domains that are found in drosophilae, mammals and plants. The Toll
family of proteins share homology in their signalling domains with
IL-1RI; this family includes Drosophila Toll, plant R proteins, and
mammalian TLRs and NLRs. CARD, caspase activation and
recruitment; IL-1RI, type I IL-1 receptor; LRR, leucine rich repeat;
NALP1, NACHT, leucine rich repeat and pyrin domain containing 1;
NLR, NOD-like receptor; PYD, pyrin domain; TLR, Toll-like receptor.
Page 3 of 14
(page number not for citation purposes)
of the NALP1 inflammasome other proteins with homology to
NALP1 were also found to form similar large intracellular
complexes. NALP1 recruits the ASC adaptor protein, as well
as caspase-1 and caspase-5, to form its inflammasome [25],
thereby activating IL-1β from its inactive pro form. In vitro
studies suggest that the bacterial cell wall product muramyl
dipeptide (MDP) binds directly and activates NALP1,
although some in vivo studies have been inconclusive on this
point [26]. The involvement of ASC in the assembly of the
NALP1 inflammasome is also somewhat controversial,
because in vitro reconstitution experiments have demon-
strated that ASC enhances but is not an absolute
requirement for NALP1-mediated caspase-1 activation [18],
although it may be required in vivo [17].
NALP1 is widely expressed at low levels in many cell types,
but it is highly expressed in immune cells, particularly T cells
and Langerhans’ cells [27]. There are two splice variants of
NALP1, one of which does not contain an LRR. Deletion of
this domain renders the protein active and able to bind ATP,
without need for MDP binding to prime the complex [18].
Variants of NALP1 confer susceptibility to vitiligo, a condition
in which white patches appear on the skin due to a loss of
pigment-producing cells [28]. Absence of the LRR domain
leads to constitutive activation of the NALP1 inflammasome,
suggesting that there is no requirement for ligand binding to
facilitate cleavage of IL-1β, with associated elevated IL-1β
serum levels found in patients with vitiligo. NALP1 can also
induce apoptosis in a variety of cell types, and over-expres-
sion stimulates caspase-mediated apoptosis [23,24,29].
NALP3 inflammasome
NALP3 (cryopyrin, PYPAF1, CIAS1, CLR1.1, NLRP3) also
forms an inflammasome complex, similar to NALP1 [16],
which mediates intracellular processing of proinflammatory
caspases and cytokine production [30]. This inflammasome
has largely been studied in the human acute monocytic
leukemia cell line THP-1, and its precise physiological role in
primary cells is yet to be fully elucidated. This inflammasome
is comprised of NALP3; ASC; and pyrin protein, which
contains a pyrin domain (PYD), caspase-1 and Cardinal. The
function of NALP3 is better characterized than those of other
NALP proteins, and its inflammasome assembles in response
to both exogenous and endogenous PAMPs and DAMPs.
Activators of the NALP3 inflammasome include bacterial
peptidoglycan; extracellular ATP, which activates the
purigenic P2X7 receptor [31]; low intracellular potassium
[32]; nigericin [33]; changes in ionic composition and uric
acid crystals within the cyoplasm [32]; and the presence of
DNA/RNA [34] and silica [35-37], which have both recently
been described.
Mutations in the NALP3 (NLRP3, CIAS1) gene, which
encodes the NALP3 protein, have been associated with a
group of autoinflammatory diseases termed the cryopyrin-
associated periodic syndromes (CAPS; cyropyrinopathies)
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Figure 2
The NALP1 and NALP3 inflammasome complexes. Both NALP1 and NALP3 associate through homotypic interactions between CARD, ASC and
the PYD domains. NALP3 requires a secondary adaptor protein Cardinal to facilitate the activation of caspase-1 and the subsequent cleavage of
pro-IL-1, in addition to the adaptor protein ASC. This is not required for the NALP1 inflammasome, which has additional FIIND and CARD domains
attached to the core NALP1 protein. ASC, apoptosis-associated speck-like protein; CARD, caspase activation and recruitment; FIIND, domain with
a function to find; IL, interleukin; LRR, leucine rich repeat; NALP, NACHT, leucine rich repeat and pyrin domain containing 1; PYD, pyrin domain.
[38,39]. These rare monogenic conditions include familial
cold autoinflammatory syndrome; Muckle-Wells syndrome;
and chronic infantile neurologic, cutaneous and articular
syndrome (CINCA)/neonatal onset multisystem inflammatory
disease (NOMID). CAPS are caused by gain of function
mutations [40] and are thought to share a common mecha-
nism, whereby the closed and inactive structure of NALP3 is
disrupted by the various mutations, leading to activation of
the inflammasome complex and IL-1β release [41].
The CAPS disorders are classified individually, but they have
overlapping symptoms that include fevers, urticarial skin
rashes, varying degrees of arthragias/arthritis, neutrophil-
mediated inflammation and an acute-phase response [42].
CINCA/NOMID is the most severe clinical phenotype, with
signs of central nervous system inflammation and skeletal
malformations. Functional studies of macrophages from
patients with CINCA/NOMID and Muckle-Wells syndrome
have revealed constitutive increases in the secretion of IL-1β
and IL-18 [43-45], suggesting that mutations in NALP3
(NLRP3, CIAS1) increase production of these proinflam-
matory cytokines. Preliminary data reported by Takada and
colleagues [46] indicate that a mutation in exon 3 of NALP3
(NLRP3, CIAS1) enhanced monocytic cell death in peripheral
blood mononuclear cells of a patient with a mild phenotype of
CINCA/NOMID, in response to lipopolysaccharide stimulation.
Mutations in other components of the NALP3 inflammasome
platform have also been shown to perpetuate excessive IL-1β
production. Pyrin (the protein encoded by the MEFV gene) is
mutated in familial Mediterranean fever, an autosomal
recessive autoinflammatory disorder in which mutated pyrin is
thought to lead to a reduced ability to moderate IL-1β activity
[47]. Pyrin interacts with the NALP3 and ASC proteins
through homotypic PYD-PYD domains, and it has been
proposed by some workers that pyrin negatively regulates
caspase-1 by competing for binding with ASC. In patients
with familial Mediterranean fever the mutated MEFV results in
altered conformation of the B30.2 (SPRY) domain at the
carboxyl-terminus, leading to impaired ligand binding and
thereby affecting inflammasome activity and IL-1β production
[48]. Impaired pyrin-mediated IL-1β regulation is also
implicated in the pathogenesis of an autosomal dominant
autoinflammatory condition termed pyogenic sterile arthritis,
pyoderma gangrenosum and acne (PAPA) syndrome. In
these patients a mutation in the PSTPIP1 (proline serine
threonine phosphatase-interacting protein 1) gene leads to an
increased interaction between PSTPIP and pyrin, resulting in
reduced modulation of the NALP3 inflammasome by pyrin [49].
This, in turn, causes a proinflammatory clinical phenotype; thus,
there is a biochemical pathway that is common to both familial
Mediterranean fever and PAPA, although the precise
mechanisms have not been fully elucidated [50].
Both the NALP3 (NLRP3, CIAS1) and MEFV genes were
also associated with psoriatic juvenile idiopathic arthritis [51],
suggesting the potential for shared disease mechanisms
between various autoinflammatory syndromes, involving
abnormal production of IL-1β. The MEFV gene is also
mutated in a significant proportion of patients with ulcerative
colitis, with a number of these having an associated
inflammatory arthritis [52,53]. NALP3 expression may also be
increased in complex conditions such as hypertension [54],
rheumatoid arthritis [55] and osteoarthritis [56], although the
precise roles in these conditions are yet to be elucidated.
NALP3 and biological therapy
Activation of the NALP3 inflammasome leads to production of
active cleaved forms of IL-1β and IL-18. Biological therapies
that target IL-1β, and the proinflammatory effects of this
cytokine, include receptor antagonists (IL-1 receptor antago-
nist) and biological molecules such as monoclonal antibodies
and soluble receptors that block IL-1β (see below). Martinon
and coworkers [57] demonstrated that the NALP3 inflamma-
some was activated by monosodium urate crystals, which are
deposited in joints and periarticular tissues in gout, and by
crystals of calcium pyrophosphate dihydrate, which is the
causative agent in pseudogout, leading to the maturation of IL-
1β and IL-18. The mouse model of monosodium urate crystal
induced inflammation has successfully been treated with
anakinra [57], a recombinant the IL-1 receptor antagonist, and
this work has led to successful human trials and a pilot study
of 10 patients with gout. All of these patients responded to
treatment with anakinra [58], demonstrating the potential to
treat gout and pseudogout patients with this agent [59,60].
Anakinra has also been used therapeutically in a number of
diseases that are associated with excessive IL-1β production,
including Muckle-Wells syndrome [61-68], familial cold auto-
inflammatory syndrome [65,69-73], NOMID/CINCA [74-76]
and Schnitzler’s syndrome [77] (Table 1).
The NALP3 inflammasome may also be associated with
common autoimmune diseases with IL-1β involvement, inclu-
ding rheumatoid arthritis. The human IL-1β monoclonal
antibody ACZ855 (produced by Novartis, basel, Switzerland)
has been used in a small clinical study of patients with
rheumatoid arthritis, and initial findings indicate greater
efficiency of ACZ855 in rheumatoid arthritis compared with
anakinra, and that the half-life is extended [78].
IL-1β Trap (rilonacept), a fusion protein consisting of human
cytokine receptor extracellular domains and the Fc portion of
human IgG1, incorporates the extracellular signalling domain
of both IL-1 receptors, namely the type I IL-1 receptor and the
IL-1 accessory protein. Rilonacept has been used in pilot
studies for the treatment of systemic-onset juvenile idiopathic
arthritis, atherosclerosis and CAPS [79].
In patients with rheumatoid arthritis receiving the biological
response modifier (biologic) infliximab, a monoclonal anti-
body to tumour necrosis factor (TNF), there were signifi-
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cantly lower NALP3 transcript levels in those patients who
later were classified as responders (according to the EULAR
[European League Against Rheumatism] DAS28 [Disease
Activity Score using 28 joint counts] criteria) before starting
treatment (baseline) with this therapy [80]. NALP3 mRNA
levels were reduced further after treatment, suggesting that
the NALP3 inflammasome plays a specific role in the
pathogenesis of rheumatoid arthritis and in the response of
these patients to treatment.
These preliminary data contrast with the findings of Karababa
and coworkers [81] in the experimental in vivo antigen-
induced arthritis model, in which it was recently demon-
strated that NALP3 and Ipaf were not necessary for the
development of arthritis, but that the ASC adaptor protein
was essential. It was suggested that there is involvement of
an inflammasome complex containing ASC in this model, with
possible interactions with other members of the NALP family.
Inflammasomes and inflammatory skin disease
There has been considerable recent interest in the patho-
genesis of other autoinflammatory skin diseases such as
psoriasis and contact hypersensitivity. The latter is a common
T lymphocyte mediated allergic disease that is characterized
by local inflammatory skin reactions, following contact with
small reactive compounds called haptens, in which the
inflammatory skin lesions are associated with inflammasome
activation. In psoriasis, there is activation of caspase-1 and
IL-18 secretion, which is regulated in a p38 mitogen-
activated protein kinase/caspase-1 dependent manner [82].
Ipaf inflammasome
The Ipaf (NLRC4, CARD12, CLAN, CLR2.1) protein, which is
homologous to NALP1 and NALP3, also forms an inflamma-
some in response to the detection of flagellin within the cyto-
plasm, and this also causes activation of caspase-1 [83,84].
The Ipaf inflammasome contains an amino-terminal CARD, a
Available online http://arthritis-research.com/content/10/6/228
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Table 1
IL-1 blockade in NLR-related disease
Autoinflammatory disease Gene mutated Activator IL-1 antagonist used References
Muckle-Wells syndrome (MWS) NALP3 (CIAS1/NLRP3) Anakinra [61-68]
Rilonacept [79]
Familial cold autoinflammatory NALP3 (CIAS1/NLRP3) Anakinra [65,69-73]
syndrome (FCAS, FCU) Rilonacept [79]
Chronic infantile neurological NALP3 (CIAS1/NLRP3) Anakinra [69-71]
cutaneous and articular syndrome/ Rilonacept [79]
neonatal onset multisystem inflammatory 
disease (CINCA/NOMID) [43]
Familial Mediteranean fever (FMF) [44] MEFV Anakinra [165-168]
Pyogenic arthritis, pyoderma PSTPIP1 Anakinra [169,170]
gangrenosum and acne syndrome (PAPA)
Vitiligo [86] NALP1 (NLRP1) ?
Gout MSU Anakinra [58,59]
Pseudogout CPPD Anakinra [60]
Hyperimmunoglobulin D syndrome (HIDS) Mevalonate kinase Anakinra [166,171]
Systemic-onset juvenile idiopathic Anakinra
arthritis (SoJIA) Rilonacept [79]
Behçet’s disease (BD) IL-1β polymorphism Anakinra [172-174]
Schnitzler’s syndrome Anakinra [77]
Blau syndrome (BS)/early onset sarcoidosis NOD2 Anakinra [160]
Crohn’s disease (CD) NOD2 Anakinra (Ineffective) [158]
Ulcerative colitis (UC) [52,53] MEFV (in a proportion ?
of patients)
Other diseases
Hydatidiform mole [87] NALP7 (NOD12,NLRP7) ?
Hypertension [54] NALP3 ?
Asthma [175] NOD1 ?
IL, interleukin; NLR, NOD-like receptor.
central NACHT domain and a carboxyl-terminal LRR, and
activation of this complex induces the combined activation of
the TLR and NLR pathways. The extracellular portion of
flagellin is detected by TLR5, and the intracellular portion of
flagellin promotes formation of this inflammasome [85]. The
appearance of flagellin within the cytoplasm, which announ-
ces the arrival of a virulent form of bacteria, prompts the
development of both an adaptive response (initiated by TLR5)
and an innate immune response. This combined intracellular
and extracellular recognition of microbial components
mediates rapid pathogen clearance [14].
Mutations in other NALP family members
Mutations in genes encoding other NALP family members
also have pathogenic consequences: the NALP1 locus is
associated with vitiligo-associated autoimmune disease
[28,86]; NALP7 (NOD12, NLRP7, PYPAF3, CLR19.4)
mutations may result in hydatidiform mole [87]; CIITA
mutations are associated with bare lymphocyte syndrome
[88] and multiple sclerosis [89]; and NOD2 mutations are
associated with Crohn’s disease and Behçet’s syndrome
[90,91]. All of these disease associations emphasize the role
played by the NALP family in the pathogenesis of the
autoinflammatory-autoimmune disease continuum [92].
Although the NALP1, NALP3 and Ipaf inflammasomes were
originally regarded as separate complexes that assemble upon
the detection of different stimuli, it is possible that the central
component may induce activation of various complexes in a
different manner, depending on the nature of the stimuli. Thus,
ASC and Ipaf were originally described as being part of
different complexes, and Ipaf and caspase-1 (but not ASC)
are implicated in Legionella flagellin recognition [85]. Shigella
induces caspase-1 activation and IL-1β production by a
mechanism involving both ASC and Ipaf [93], which are
regarded as components of separate inflammasomes.
The Nodosomes
NOD1 and NOD2
NOD1 and NOD2 are two further NLRs that recognize
PAMPs and are implicated in innate immune responses.
NOD1 recognizes γ-D-glutamyl-meso-diaminopimelic acid
(DAP), a dipeptide derived from peptidoglycans of most
Gram-negative bacteria; NOD2 senses MDP, which is a
constituent of most Gram-negative and Gram-positive
bacterial peptidoglycans [94]. In the basal state, the LRR
region of NOD2 represses activation of the nucleotide-binding
domain, preventing spontaneous oligomerization [18];
however, upon DAP and MDP sensing, a conformational
change in the LRR region allows for oligomerization of the
NACHT domain and subsequent activation of CARD, thereby
allowing for downstream activation of effector molecules [95].
NOD signalling
In response to muropeptides, both NOD1 and NOD2 recruit
an adaptor protein containing a CARD domain, namely the
serine threonine kinase receptor-interacting protein (RIP)2
(also known as RICK and CARDIAK), which assembles via
CARD-CARD homotypic binding. This, in turn, allows for
oligomerization of RIP2 and interaction with the IκB kinase
(IKK) complex (IKKα, IKKβ, and nuclear factor-κB [NF-κB]
essential modifier, abbreviated to NEMO). Ubiquitination of
this inhibitory complex results in the release and nuclear
translocation of the NF-κB transcription factor and subse-
quent transcription of NF-κB-dependent proinflammatory
genes [96,97] (Figure 3). RIP2 is crucial in this signalling
pathway, as demonstrated in RIP2-/- mice [98], in which
MDP-induced NOD activation of NF-κB is abolished. RIP2
has also recently been shown to signal specifically for NOD
but not TLRs [99], and indeed NOD signalling is independent
of Myd88, which is a key adaptor molecule in the TLR
signalling pathway [100]. In addition to NF-κB activation,
NOD signalling also leads to activation of mitogen-activated
protein kinases, further enhancing the proinflammatory state
[99,101].
NOD1
NOD1 has been extensively implicated in the handling of a
variety of bacteria, and the intracellular nature of such
sensing has also been confirmed. An invasive strain of the
Gram-negative bacterium Shigella flexneri can also activate
NF-κB and IL-8 expression in colonic epithelial cells, but the
noninvasive strain does not have this effect. This process is
driven by lipopolysaccharide but does not involve sensing
by TLRs [102,103]; indeed, colonic epithelium is refractory
to extracellular lipopolysaccharide stimulation, thereby
preventing aberrant cellular responses to commensal
bacteria. Subsequent to this work, it was demonstrated that
oligomerization of NOD1 was responsible for the intra-
cellular pathogenicity of S. flexneri and consequent
activation of NF-κB [101,103]. Helicobacter pylori, another
Gram-negative noninvasive bacterium, is recognized by
NOD1 in epithelial cells in cag pathogenicity island positive
bacteria [104]. More severe pathological consequences of
H. pylori infection are determined by the cag pathogenicity
island, and only strains containing cag pathogenicity island
activate NF-κB proinflammatory cytokines [105]. The
delivery of muropeptide from this noninvasive bacterium
appears to be via a type IV secretion system, directly into
the host cell [106], again suggesting pathogen sensing
independent of TLRs. NOD2 is also implicated in H. pylori
sensing, and the NOD2 mutant R720W increases risk for
gastric lymphoma [107], which is a recognized conse-
quence of chronic H. pylori infection.
NOD1 has also been demonstrated to be the PRR for many
other bacteria, including the common pathogens Campylo-
bacter jejuni [108], Pseudomonas aeruginosa [109],
Escherichia coli [103], and Chlamydia trachomatis and
Chlamydia muridarum, with a dominant negative NOD1, or
NOD1 depletion, being less effective in activating NF-κB in
the case of Chlamydia spp. [110].
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NOD1 mutants are implicated in disease to a lesser extent
than NOD2 mutants. The NOD1 gene is found on chromo-
some 7p14, a region that has already been linked to atopy
[111]. Weidinger and coworkers [112] analyzed 11 poly-
morphisms in the NOD1 gene for associations with atopic
phenotypes, with some polymorphisms exhibiting association
with atopic eczema and asthma. With respect to Crohn’s
disease (a chronic granulomatous inflammatory disorder of the
bowel found in patients carrying mutations in NOD2 in up to
40% of cases [90]), NOD1 mutants have not been reported
to confer disease susceptibility to this disorder [113-115].
NOD2
NOD2 mutations has been implicated in several inflammatory
disorders, including Crohn’s disease [90], Blau syndrome
[91], which is a rare autosomal dominant disorder that causes
granulomatous inflammation of the skin, arthritis, uveitis and
lymphadenopathy, as well as early onset sarcoidosis
[116,117]. NOD2 has been most extensively investigated in
inflammatory bowel disease (IBD). It was described as the
first susceptibility locus for Crohn’s disease in 2001, within
the IBD1 region on chromosome 16 [90,118]. This was the
first evidence of a link between the innate immune system
and inflammatory processes in Crohn’s disease, a disease
that was widely accepted to be T-helper-1 driven until that
point, and therefore assumed to be a disease of the adaptive
immune system [119].
Much work since then has addressed whether mutations in
the NOD2 gene lead to a gain or loss of function of the NOD
protein. There are three major NOD2 single nucleotide poly-
morphisms (SNPs), two missense mutations (Arg702Trp and
Gly908Arg) and one frameshift mutation (3020insC→1007fs)
[118,120]. All of these SNPs affect the LRR region of the
NOD2 protein, resulting in defective sensing of MDP [121].
The inability of mutant NOD2 to detect microbial constituents
translates into a lack of activation of NF-κB and subsequent
decreased IL-1β release [122]. However, this does not
concur with the clinical picture of active Crohn’s disease, and
indeed it has been known for many years that IL-1β levels are
significantly increased in patients with active Crohn’s disease
[123], as are other cytokines that are NF-κB dependent, such
as IL-6 and IL-12 [124,125].
This apparent dichotomy may be explained by appreciating
the cellular function of NOD2 and its interaction with other
PRRs, such as TLRs. Peptidoglycan, from which MDP is
derived, is also the PAMP recognized by TLR2; on stimulating
NOD-/- cells, which are incapable of sensing MDP, with
peptidoglycan, there is an enhanced TLR2 response. Levels
of the c-rel subunit of NF-κB increase, thereby regulating an
increase in IL-12 and hence increased inflammation. These
data suggest an inhibitory regulatory function of NOD2 with
respect to TLR2 signalling, because in cells with wild-type
NOD2, which sense MDP, the TLR2 peptidoglycan response
Available online http://arthritis-research.com/content/10/6/228
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Figure 3
Nodosome signalling. Ligand binding to the LRR region regulates oligomerization of the NACHT domain and homotypic interactions between
CARD domains and RIP2. Ubiquitination of the IKK complex following oligomerization of RIP2 allows for nuclear translocation of NF-κB and
subsequent upregulation of proinflammatory cytokines. CARD, caspase activation and recruitment; IKK, IκB kinase; LRR, leucine rich repeat;
NEMO, NF-κB essential modifier; NF-κ, nuclear factor-κB; RIP, receptor-interacting protein.
is inhibited [126,127]. In human monocytes, Borm and co-
workers [128] have demonstrated that low levels of MDP
stimulate a synergistic response between TLR2 and NOD2,
but this synergism is lost at higher doses of MDP, with
decreased inflammatory responses. Mutant NOD2 cannot
sense MDP, and so this inhibitory effect is lost and the TLR2
response is heightened [126-128]. The dose-dependent
inhibition of TLR2 may help to explain why functioning
NOD2 is able to handle commensal bacteria in the gastro-
intestinal tract, without the aberrant inflammation seen in
NOD2 mutants. However, other studies have failed to
corroborate the TLR2 story, with Kobayashi and colleagues
[129] reporting similar responses to TLR ligands in wild-
type and NOD2-/- cells, and indeed an increase in IL-6 in
wild-type NOD2 cells on stimulation with Pam3CSK4, a
TLR2 ligand [129].
A further consideration is the role that NOD2 plays in mucosal
defence. It is widely postulated that the pathogenesis of
Crohn’s disease is, at least in part, due to defective intestinal
barrier function. Paneth cells, found in the crypts of Lieberkuhn
in the small intestine, are specialized intestinal innate immune
cells, which are responsible for the production and secretion
of antimicrobial peptides, such as defensins, in response to
luminal bacterial products, such as MDP [130,131].
NOD2 is most abundantly distributed in Paneth cells in the
terminal ileum of patients with Crohn’s disease and healthy
control individuals, particularly in ileal crypts [132]. The
mutated NOD2 phenotype is most frequently associated with
ileal disease [133,134], which therefore may implicate
defective Paneth cell function as a disease mechanism.
Indeed, decreased expression of human α-defensins HD5
and HD6 is reported in Crohn’s disease patients who have
mutated NOD2, leading to a subsequent increase in
microbial flora in transgenic mice models [135]. The increase
in luminal bacteria, and the decreased clearance, may
therefore perpetuate bacterial stasis in the intestinal crypts
and further exacerbate the inflammatory response [129].
Finally, NOD2 mutations may decrease the expression of
the regulatory cytokine IL-10 in dendritic cells at least,
which may implicate NOD2 in disordered regulation of
inflammatory cytokines, such as TNF, IL-12 and suppressor
T cells, and allow for an aberrant inflammatory response
[136]. However, despite the NOD2 story in Crohn’s disease
being quite compelling, it does not explain the whole picture
in this polygenic disorder. Recent genome studies have
implicated several other new genes that confer suscepti-
bility to Crohn’s disease, including two autophagy genes,
namely ATG16L1 [137] and IRGM [138], as well as IL-23
receptor polymorphisms [139], suggesting a role for
aberrant T-helper-17 responses. Also, various studies have
shown that the NOD2 gene does not confer susceptibility
to Crohn’s disease in certain populations, such as Japanese
cohorts [140,141].
An association of NOD2 with the other major IBD, ulcerative
colitis, is less clear, with initial studies showing no association
of ulcerative colitis and NOD2 [90]. Subsequent work has
demonstrated that NOD2 may modify the risk for developing
ulcerative colitis in patients who have the IBD susceptibility
locus IBD5 [142]. However, as previously discussed, asso-
ciations in ulcerative colitis patients with the pyrin protein
indicate that these may modify susceptibility to ulcerative
colitis particularly with inflammatory arthritis [52,53].
NOD2 has other disease associations also, such as Blau
syndrome [143]. A total of four missense mutations (R334Q,
R334W, L469F and E383) have been identified as conferring
disease susceptibility [91,144], all of which are located in the
central NACHT domain, which is in contrast to the LRR
variants seen in Crohn’s disease. These variants lead to
NF-κB upregulation on MDP stimulation [145,146].
Early onset sarcoidosis shares considerable phenotypic
overlap with Blau syndrome and has also been associated
with the R334W mutation in NOD2 [116,146]. However,
other granulomatous disorders, such as adult-onset sarcoidosis
and Wegener’s granulomatosis, have not been associated
with NOD2 [147,148].
NOD2 has also been studied in sepsis. Brenmoehl and
coworkers [149] showed that mortality from sepsis in the
intensive care unit setting is higher in patients carrying the
frameshift variant in NOD2 (57% versus 31%), in cohorts of
patients who were broadly matched for clinical indices of
severity of disease. This may represent the consequences of
decreased intracellular sensing of bacterial products and
decreased bacterial clearance, leading to a potentiation of
infection and proinflammatory cascades, ultimately leading to
cardiovascular collapse and shock. In transplant medicine,
donor and recipient NOD2 status appears important in graft
versus host disease and transplant mortality in allogeneic
stem cell transplantation, with an increased likelihood of both
of these conditions occurring in the presence of an
increasing number of NOD2 mutations in donor and recipient
cohorts [150].
In relation to inflammatory arthritis, there is relatively little in
the literature suggesting a role for the nodosome. Joosten
and colleagues recently demonstrated that NOD2 deficiency
in mice is protective against acute joint inflammation and early
cartilage destruction induced by bacteria [151]. NOD1
deficiency leads to increased inflammation and cytokine
production. This pattern was replicated in human peripheral
blood mononuclear cells with NOD1/2 mutants [151].
However, it was previously shown in several studies that
NOD2 mutant alleles do not confer susceptibility to rheuma-
toid arthritis [152].
Until recently, evidence for overlap or crosstalk between
individual NLRs had not been identified. However, it appears
Arthritis Research & Therapy    Vol 10 No 6 Mathews et al.
Page 8 of 14
(page number not for citation purposes)
that NOD2 and NALP3 SNPs may have a synergistic
contribution toward susceptibility to Crohn’s disease.
Cummings and coworkers [153] showed that the rs1539019
SNP in the NALP3 (NLRP3, CIAS1) gene conferred suscep-
tibility to Crohn’s disease in the presence of a NOD2
mutation (P = 0.0006). With high levels of IL-1 seen in
Crohn’s disease patients, mutations within NALP3 make this
an attractive candidate gene for further study in Crohn’s
disease. Of further interest, recent genome-wide association
studies are consistently uncovering new genes that are
associated with Crohn’s disease, with around 30 genes now
implicated in susceptibility to this disease [154].
NOD2 and biological therapy
Infliximab was the first anti-TNF therapy to be used in the
treatment of Crohn’s disease, with response rates of around
70% and remission rates of around 30% [155]. However,
two large studies [156,157] have not suggested a correlation
between NOD2 mutations and response or predictors of
response or nonresponse to infliximab. Anakinra, however,
makes Crohn’s disease worse [158]. In Blau syndrome there
are case reports of two patients, with the R334W change in
the NACHT domain, responding to infliximab, with almost
entire resolution of symptoms, but not to etanercept [159].
Whether this effect is mutation specific or a global effect of
infliximab cannot be determined. There are also limited data
suggesting a possible role for anakinra in the treatment of
Blau syndrome, with normalization of cytokines and sympto-
matic improvement in a patient after treatment [160].
Conclusion
The two most studied groups of PRRs, namely the TLRs and
NLRs, have been shown not only to have independent effects
but also to have important two-way crosstalk between these
pathways. The interactions between these two major
pathways are being investigated and currently hint at the
complexity of the innate immune response to PRRs. PRRs
can activate either TLRs or NLRs, or both, thereby initiating a
more rapid and enhanced response. Monosodium urate has
been shown to act in synergy with lipopolysaccharide, a
ligand for TLR4, inducing an enhanced response after co-
stimulation of the NLR and TLR pathway, and release of IL-1β
[161]. In addition, there is evidence of alternative pathways
that result in NF-κB activation and the production of cyto-
kines, in a similar manner to TLRs and NLRs. Anti-neutrophil
cytoplasmic antibody, an autoantibody that is directed against
the enzymes located in neutrophils and monocytes,
specifically against proteinase 3, primes human monocytic
cells, via protease-activated receptor-2, to produce cytokines
[162]. These antibodies prime the innate immune system,
following an upstream event whereby the presence of
bacterial components led to stimulation by TLR and NOD1/2
[163], subsequently leading to secretion of proinflammatory
cytokines. Matsumoto and colleagues [164] reported that
proteinase 3 is downregulated in rheumatoid arthritis patients
after treatment with the anti-TNF therapy infliximab. This
suggests that these mechanisms actively participate in
inflammatory processes, and that these interactions may not
be exclusive of one another.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This work was supported by grants from the Sir Jules Thorn ‘Seed
Corn’ Fund and the Charitable Foundation of the Leeds Teaching Hos-
pitals (Dr Sprakes is currently funded by the Charitable Trustees,
Leeds General Infirmary).
References
1. Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE, Sims
JE: Four new members expand the interleukin-1 superfamily.
J Biol Chem 2000, 275:1169-1175.
2. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan
TK, Zurawski G, Moshrefi M, Qin J, Li X, et al.: IL-33, an inter-
leukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cyto-
kines. Immunity 2005, 23:479-490.
3. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood
1996, 87:2095-2147.
4. Dinarello CA: Interleukin 1 and interleukin 18 as mediators of
inflammation and the aging process. Am J Clin Nutr 2006, 83:
447S-455S.
5. Janeway CA, Jr., Medzhitov R: Innate immune recognition. Annu
Rev Immunol 2002, 20:197-216.
6. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the
adaptive immune response. Curr Opin Immunol 1997, 9:4-9.
7. Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O,
Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK,
Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B: Genetic and
physical mapping of the Lps locus: identification of the toll-4
receptor as a candidate gene in the critical region. Blood Cells
Mol Dis 1998, 24:340-355.
8. Gazzinelli RT, Denkers EY: Protozoan encounters with Toll-like
receptor signalling pathways: implications for host parasitism.
Nat Rev Immunol 2006, 6:895-906.
9. Trinchieri G, Sher A: Cooperation of Toll-like receptor signals
in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
10. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and
innate immunity. Cell 2006, 124:783-801.
11. HUGO: Nucleotide-binding domain and leucine rich repeat
containing family [http://www.genenames.org/genefamily/nlr.php]
12. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE: Nod-like proteins
in immunity, inflammation and disease. Nat Immunol 2006, 7:
1250-1257.
13. Sirard JC, Vignal C, Dessein R, Chamaillard M: Nod-like recep-
tors: cytosolic watchdogs for immunity against pathogens.
PLoS Pathog 2007, 3:e152.
14. Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell
RA: Immune recognition of Pseudomonas aeruginosa medi-
ated by the IPAF/NLRC4 inflammasome. J Exp Med 2007,
204:3235-3245.
15. Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG, Girardin SE:
The Nodosome: Nod1 and Nod2 control bacterial infections
and inflammation. Semin Immunopathol 2007, 29:289-301.
16. Martinon F, Burns K, Tschopp J: The inflammasome: a molecu-
lar platform triggering activation of inflammatory caspases
and processing of proIL-beta. Mol Cell 2002, 10:417-426.
17. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee
WP, Roose-Girma M, Erickson S, Dixit VM: Differential activation
of the inflammasome by caspase-1 adaptors ASC and Ipaf.
Nature 2004, 430:213-218.
18. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-
Maitre B, Volkmann N, Hanein D, Rouiller I, Reed JC: Reconsti-
tuted NALP1 inflammasome reveals two-step mechanism of
caspase-1 activation. Mol Cell 2007, 25:713-724.
19. Steinman L: Therapy of autoimmune disease with monoclonal
antibodies to class II gene products of the major histocom-
patibility complex. Prog Allergy 1988, 45:161-167.
Available online http://arthritis-research.com/content/10/6/228
Page 9 of 14
(page number not for citation purposes)
20. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunko-
lade BW, Centola M, Mansfield E, Gadina M, Karenko L, Petters-
son T, McCarthy J, Frucht DM, Aringer M, Torosyan Y, Teppo AM,
Wilson M, Karaarslan HM, Wan Y, Todd I, Wood G, Schlimgen R,
Kumarajeewa TR, Cooper SM, Vella JP, Amos CI, Mulley J, Quane
KA, Molloy MG, Ranki A, Powell RJ, et al.: Germline mutations in
the extracellular domains of the 55 kDa TNF receptor, TNFR1,
define a family of dominantly inherited autoinflammatory syn-
dromes. Cell 1999, 97:133-144.
21. Ting JP, Kastner DL, Hoffman HM: CATERPILLERs, pyrin and
hereditary immunological disorders. Nat Rev Immunol 2006, 6:
183-195.
22. Martinon F, Tschopp J: Inflammatory caspases and inflamma-
somes: master switches of inflammation. Cell Death Differ
2007, 14:10-22.
23. Chu ZL, Pio F, Xie Z, Welsh K, Krajewska M, Krajewski S, Godzik
A, Reed JC: A novel enhancer of the Apaf1 apoptosome
involved in cytochrome c-dependent caspase activation and
apoptosis. J Biol Chem 2001, 276:9239-9245.
24. Hlaing T, Guo RF, Dilley KA, Loussia JM, Morrish TA, Shi MM,
Vincenz C, Ward PA: Molecular cloning and characterization of
DEFCAP-L and -S, two isoforms of a novel member of the
mammalian Ced-4 family of apoptosis proteins. J Biol Chem
2001, 276:9230-9238.
25. Petrilli V, Papin S, Tschopp J: The inflammasome. Curr Biol
2005, 15:R581.
26. Bruey JM, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C,
Kress CL, Bailly-Maitre B, Li X, Osterman A, Matsuzawa S, Ter-
skikh AV, Faustin B, Reed JC: Bcl-2 and Bcl-XL regulate proin-
flammatory caspase-1 activation by interaction with NALP1.
Cell 2007, 129:45-56.
27. Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Marti-
non F, van Bruggen R, Tschopp J: Inflammasome components
NALP 1 and 3 show distinct but separate expression profiles
in human tissues suggesting a site-specific role in the inflam-
matory response. J Histochem Cytochem 2007, 55:443-452.
28. Jin Y, Birlea SA, Fain PR, Spritz RA: Genetic variations in NALP1
are associated with generalized vitiligo in a Romanian popula-
tion. J Invest Dermatol 2007, 127:2558-2562.
29. Liu F, Lo CF, Ning X, Kajkowski EM, Jin M, Chiriac C, Gonzales C,
Naureckiene S, Lock YW, Pong K, Zaleska MM, Jacobsen JS, Sil-
verman S, Ozenberger BA: Expression of NALP1 in cerebellar
granule neurons stimulates apoptosis. Cell Signal 2004, 16:
1013-1021.
30. Martinon F, Agostini L, Meylan E, Tschopp J: Identification of
bacterial muramyl dipeptide as activator of the NALP3/cry-
opyrin inflammasome. Curr Biol 2004, 14:1929-1934.
31. Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller
BH, Griffiths RJ, Gabel CA: Altered cytokine production in mice
lacking P2X(7) receptors. J Biol Chem 2001, 276:125-132.
32. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J:
Activation of the NALP3 inflammasome is triggered by low
intracellular potassium concentration. Cell Death Differ 2007,
14:1583-1589.
33. Perregaux D, Barberia J, Lanzetti AJ, Geoghegan KF, Carty TJ,
Gabel CA: IL-1 beta maturation: evidence that mature
cytokine formation can be induced specifically by nigericin. J
Immunol 1992, 149:1294-1303.
34. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ,
Parks RJ, Tschopp J: The inflammasome recognizes cytosolic
microbial and host DNA and triggers an innate immune
response. Nature 2008, 452:103-107.
35. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock
KL, Fitzgerald KA, Latz E: Silica crystals and aluminum salts
activate the NALP3 inflammasome through phagosomal
destabilization. Nat Immunol 2008, 9:847-856.
36. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly
LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS: The
Nalp3 inflammasome is essential for the development of sili-
cosis. Proc Natl Acad Sci USA 2008, 105:9035-9040.
37. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT,
Tschopp J: Innate immune activation through Nalp3 inflamma-
some sensing of asbestos and silica. Science 2008, 320:674-
677.
38. Hoffman HM, Wanderer AA, Broide DH: Familial cold auto-
inflammatory syndrome: phenotype and genotype of an auto-
somal dominant periodic fever. J Allergy Clin Immunol 2001,
108:615-620.
39. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E,
Teillac-Hamel D, Fischer A, de Saint Basile G: Chronic infantile
neurological cutaneous and articular syndrome is caused by
mutations in CIAS1, a gene highly expressed in polymor-
phonuclear cells and chondrocytes. Am J Hum Genet 2002,
71:198-203.
40. Dowds TA, Masumoto J, Zhu L, Inohara N, Nunez G: Cryopyrin-
induced interleukin 1beta secretion in monocytic cells:
enhanced activity of disease-associated mutants and require-
ment for ASC. J Biol Chem 2004, 279:21924-21928.
41. Tschopp J, Martinon F, Burns K: NALPs: a novel protein family
involved in inflammation. Nat Rev Mol Cell Biol 2003, 4:95-
104.
42. Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolod-
ner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R,
Hoffman HM, Kastner DL: The clinical continuum of cryopy-
rinopathies: novel CIAS1 mutations in North American
patients and a new cryopyrin model. Arthritis Rheum 2007, 56:
1273-1285.
43. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT,
Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg
HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow
H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams
BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron
K, O’Shea JJ, Kastner DL, et al.: De novo CIAS1 mutations,
cytokine activation, and evidence for genetic heterogeneity in
patients with neonatal-onset multisystem inflammatory
disease (NOMID): a new member of the expanding family of
pyrin-associated autoinflammatory diseases. Arthritis Rheum
2002, 46:3340-3348.
44. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN,
Tschopp J: NALP3 forms an IL-1beta-processing inflamma-
some with increased activity in Muckle-Wells autoinflamma-
tory disorder. Immunity 2004, 20:319-325.
45. Janssen R, Verhard E, Lankester A, Ten Cate R, van Dissel JT:
Enhanced interleukin-1beta and interleukin-18 release in a
patient with chronic infantile neurologic, cutaneous, articular
syndrome. Arthritis Rheum 2004, 50:3329-3333.
46. Takada H, Ishimura M, Inada H, Ohga S, Kusuhara K, Moroi Y,
Furue M, Hara T: Lipopolysaccharide-induced monocytic cell
death for the diagnosis of mild neonatal-onset multisystem
inflammatory disease. J Pediatr 2008, 152:885-887.
47. Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G:
Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial
Mediterranean fever gene product. Biochem Biophys Res
Commun 2003, 302:575-580.
48. Stojanov S, Kastner DL: Familial autoinflammatory diseases:
genetics, pathogenesis and treatment. Curr Opin Rheumatol
2005, 17:586-599.
49. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes
S, Lovett M: Mutations in CD2BP1 disrupt binding to PTP
PEST and are responsible for PAPA syndrome, an autoinflam-
matory disorder. Hum Mol Genet 2002, 11:961-969.
50. McDermott MF: A common pathway in periodic fever syn-
dromes. Trends Immunol 2004, 25:457-460.
51. Day TG, Ramanan AV, Hinks A, Lamb R, Packham J, Wise C,
Punaro M, Donn RP: Autoinflammatory genes and susceptibil-
ity to psoriatic juvenile idiopathic arthritis. Arthritis Rheum
2008, 58:2142-2146.
52. Giaglis S, Mimidis K, Papadopoulos V, Thomopoulos K,
Sidiropoulos P, Rafail S, Nikolopoulou V, Fragouli E, Kartalis G,
Tzioufas A, Boumpas D, Ritis K: Increased frequency of muta-
tions in the gene responsible for familial Mediterranean fever
(MEFV) in a cohort of patients with ulcerative colitis: evidence
for a potential disease-modifying effect? Dig Dis Sci 2006, 51:
687-692.
53. Sari S, Egritas O, Dalgic B: The familial Mediterranean fever
(MEFV) gene may be a modifier factor of inflammatory bowel
disease in infancy. Eur J Pediatr 2008, 167:391-393.
54. Omi T, Kumada M, Kamesaki T, Okuda H, Munkhtulga L, Yanagi-
sawa Y, Utsumi N, Gotoh T, Hata A, Soma M, Umemura S,
Ogihara T, Takahashi N, Tabara Y, Shimada K, Mano H, Kajii E,
Miki T, Iwamoto S: An intronic variable number of tandem
repeat polymorphisms of the cold-induced autoinflammatory
syndrome 1 (CIAS1) gene modifies gene expression and is
associated with essential hypertension. Eur J Hum Genet
Arthritis Research & Therapy    Vol 10 No 6 Mathews et al.
Page 10 of 14
(page number not for citation purposes)
2006, 14:1295-1305.
55. Rosengren S, Hoffman HM, Bugbee W, Boyle DL: Expression
and regulation of cryopyrin and related proteins in rheumatoid
arthritis synovium. Ann Rheum Dis 2005, 64:708-714.
56. Mahr S, Burmester GR, Hilke D, Göbel U, Grützkau A, Häupl T,
Hauschild M, Koczan D, Krenn V, Neidel J, Perka C, Radbruch A,
Thiesen HJ, Müller B: Cis- and trans-acting gene regulation is
associated with osteoarthritis. Am J Hum Genet 2006, 78:793-
803.
57. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-asso-
ciated uric acid crystals activate the NALP3 inflammasome.
Nature 2006, 440:237-241.
58. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1
inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:
R28.
59. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P,
McDermott MF: Management of treatment resistant inflamma-
tion of acute on chronic tophaceous gout with anakinra. Ann
Rheum Dis 2007, 66:1683-1684.
60. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF: Suc-
cessful treatment of resistant pseudogout with anakinra.
Arthritis Rheum 2008, 58:631-633.
61. Alexander T, Klotz O, Feist E, Ruther K, Burmester GR, Pleyer U:
Successful treatment of acute visual loss in Muckle-Wells
syndrome with interleukin 1 receptor antagonist. Ann Rheum
Dis 2005, 64:1245-1246.
62. Dalgic B, Egritas O, Sari S, Cuisset L: A variant Muckle-Wells
syndrome with a novel mutation in CIAS1 gene responding to
anakinra. Pediatr Nephrol 2007, 22:1391-1394.
63. Gerard S, le Goff B, Maugars Y, Berthelot JM, Malard O: Lasting
remission of a Muckle-Wells syndrome with CIAS-1 mutation
using half-dose anakinra. Joint Bone Spine 2007, 74:659.
64. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF: Spectrum
of clinical features in Muckle-Wells syndrome and response to
anakinra. Arthritis Rheum 2004, 50:607-612.
65. Maksimovic L, Stirnemann J, Caux F, Ravet N, Rouaghe S, Cuisset
L, Letellier E, Grateau G, Morin AS, Fain O: New CIAS1 mutation
and anakinra efficacy in overlapping of Muckle-Wells and
familial cold autoinflammatory syndromes. Rheumatology
(Oxford) 2008, 47:309-310.
66. Mirault T, Launay D, Cuisset L, Hachulla E, Lambert M, Queyrel V,
Quemeneur T, Morell-Dubois S, Hatron PY: Recovery from deaf-
ness in a patient with Muckle-Wells syndrome treated with
anakinra. Arthritis Rheum 2006, 54:1697-1700.
67. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P: Hearing
improvement in a patient with variant Muckle-Wells syndrome
in response to interleukin 1 receptor antagonism. Ann Rheum
Dis 2006, 65:533-534.
68. Yamazaki T, Masumoto J, Agematsu K, Sawai N, Kobayashi S,
Shigemura T, Yasui K, Koike K: Anakinra improves sensory
deafness in a Japanese patient with Muckle-Wells syndrome,
possibly by inhibiting the cryopyrin inflammasome. Arthritis
Rheum 2008, 58:864-868.
69. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL,
Anderson JP, Wanderer AA, Firestein GS: Prevention of cold-
associated acute inflammation in familial cold autoinflamma-
tory syndrome by interleukin-1 receptor antagonist. Lancet
2004, 364:1779-1785.
70. Metyas SK, Hoffman HM: Anakinra prevents symptoms of
familial cold autoinflammatory syndrome and Raynaud’s
disease. J Rheumatol 2006, 33:2085-2087.
71. O’Connell SM, O’Regan GM, Bolger T, Hoffman HM, Cant A,
Irvine AD, Watson RM: Response to IL-1-receptor antagonist in
a child with familial cold autoinflammatory syndrome. Pediatr
Dermatol 2007, 24:85-89.
72. Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thomp-
son K, Churchman SM, McDermott MF, Hawkins PN: Use of
anakinra (Kineret) in the treatment of familial cold autoinflam-
matory syndrome with a 16-month follow-up. J Cutan Med
Surg 2008, 12:8-16.
73. Thornton BD, Hoffman HM, Bhat A, Don BR: Successful treat-
ment of renal amyloidosis due to familial cold autoinflamma-
tory syndrome using an interleukin 1 receptor antagonist. Am
J Kidney Dis 2007, 49:477-481.
74. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J,
Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner
ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp
MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B,
Jarvis JN, O’Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP,
Warren RW, et al.: Neonatal-onset multisystem inflammatory
disease responsive to interleukin-1beta inhibition. N Engl J
Med 2006, 355:581-592.
75. Goldbach-Mansky R, Pucino F, Kastner DL: Treatment of
patients with neonatal-onset multisystem inflammatory
disease/chronic infantile neurologic, cutaneous, articular syn-
drome: comment on the article by Matsubara et al. Arthritis
Rheum 2007, 56:2099-2101; author reply 2101-2092.
76. Lovell DJ, Bowyer SL, Solinger AM: Interleukin-1 blockade by
anakinra improves clinical symptoms in patients with neona-
tal-onset multisystem inflammatory disease. Arthritis Rheum
2005, 52:1283-1286.
77. de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG,
van der Meer JW: Beneficial response to anakinra and thalido-
mide in Schnitzler’s syndrome. Ann Rheum Dis 2006, 65:542-
544.
78. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J,
Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin
GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T: The
human anti-interleukin-1b monoclonal antibody ACZ885 is
effective in joint inflammation models in mice and in a proof
of concept study in rheumatoid arthritis patients. Arthritis Res
Ther 2008, 10:R67.
79. Tomillero A, Moral MA: Gateways to clinical trials. Methods Find
Exp Clin Pharmacol 2008, 30:231-251.
80. Mathews R, Churchman S, Church L, Coulthard L, Byryer D,
Nizam S, Saleem B, Cook GP, Emery P, McDermott MF: Effects
of TNF blockade by infliximab on inflammasome regulators in
rheumatoid arthritis patients. Ann Rheum Dis 2008, 67(suppl
1):A25.
81. Karababa M, Kolly L, Tschopp J, Busso N: Crucial role of ASC-
dependent inflammasome in murine arthritis. Arthritis Rheum
2007, 56(suppl 1):1280.
82. Johansen C, Moeller K, Kragballe K, Iversen L: The activity of
caspase-1 is increased in lesional psoriatic epidermis. J Invest
Dermatol 2007, 127:2857-2864.
83. Franchi L, Stoolman J, Kanneganti TD, Verma A, Ramphal R,
Nunez G: Critical role for Ipaf in Pseudomonas aeruginosa-
induced caspase-1 activation. Eur J Immunol 2007, 37:3030-
3039.
84. Franchi L, Amer A, Body-Malapel M, Kanneganti TD, Ozören N,
Jagirdar R, Inohara N, Vandenabeele P, Bertin J, Coyle A, Grant
EP, Núñez G: Cytosolic flagellin requires Ipaf for activation of
caspase-1 and interleukin 1beta in salmonella-infected
macrophages. Nat Immunol 2006, 7:576-582.
85. Amer A, Franchi L, Kanneganti TD, Body-Malapel M, Ozören N,
Brady G, Meshinchi S, Jagirdar R, Gewirtz A, Akira S, Núñez G:
Regulation of Legionella phagosome maturation and infection
through flagellin and host Ipaf. J Biol Chem 2006, 281:35217-
35223.
86. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett
DC, Fain PR, Spritz RA: NALP1 in vitiligo-associated multiple
autoimmune disease. N Engl J Med 2007, 356:1216-1225.
87. Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R,
Bagga R, Kircheisen R, Ao A, Ratti B, Hanash S, Rouleau GA,
Slim R: Mutations in NALP7 cause recurrent hydatidiform
moles and reproductive wastage in humans. Nat Genet 2006,
38:300-302.
88. Steimle V, Otten LA, Zufferey M, Mach B: Complementation
cloning of an MHC class II transactivator mutated in heredi-
tary MHC class II deficiency (or bare lymphocyte syndrome).
Cell 1993, 75:135-146.
89. Martinez A, Alvarez-Lafuente R, Mas A, Bartolome M, Garcia-
Montojo M, de Las Heras V, de la Concha EG, Arroyo R, Urcelay
E: Environment-gene interaction in multiple sclerosis: human
herpesvirus 6 and MHC2TA. Hum Immunol 2007, 68:685-689.
90. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP,
Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V,
Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau
C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of
NOD2 leucine-rich repeat variants with susceptibility to
Crohn’s disease. Nature 2001, 411:599-603.
91. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-
Hanu S, Hafner R, Chamaillard M, Zouali H, Thomas G, Hugot JP:
CARD15 mutations in Blau syndrome. Nat Genet 2001, 29:19-
Available online http://arthritis-research.com/content/10/6/228
Page 11 of 14
(page number not for citation purposes)
20.
92. McGonagle D, Savic S, McDermott MF: The NLR network and
the immunological disease continuum of adaptive and innate
immune-mediated inflammation against self. Semin
Immunopathol 2007, 29:303-313.
93. Suzuki T, Franchi L, Toma C, Ashida H, Ogawa M, Yoshikawa Y,
Mimuro H, Inohara N, Sasakawa C, Nunez G: Differential regula-
tion of caspase-1 activation, pyroptosis, and autophagy via
Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog
2007, 3:e111.
94. Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG,
Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D: Peptidoglycan
molecular requirements allowing detection by Nod1 and
Nod2. J Biol Chem 2003, 278:41702-41708.
95. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, Carrio R,
Merino J, Liu D, Ni J, Ni J, Núñez G: Nod1, an Apaf-1-like activa-
tor of caspase-9 and nuclear factor-kappaB. J Biol Chem
1999, 274:14560-14567.
96. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, Ogura
Y, Nunez G: An induced proximity model for NF-kappa B acti-
vation in the Nod1/RICK and RIP signaling pathways. J Biol
Chem 2000, 275:27823-27831.
97. Abbott DW, Wilkins A, Asara JM, Cantley LC: The Crohn’s
disease protein, NOD2, requires RIP2 in order to induce ubiq-
uitinylation of a novel site on NEMO. Curr Biol 2004, 14:2217-
2227.
98. Pan Q, Mathison J, Fearns C, Kravchenko VV, Da Silva Correia J,
Hoffman HM, Kobayashi KS, Bertin J, Grant EP, Coyle AJ, Sutter-
wala FS, Ogura Y, Flavell RA, Ulevitch RJ: MDP-induced inter-
leukin-1beta processing requires Nod2 and CIAS1/NALP3. J
Leukoc Biol 2007, 82:177-183.
99. Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M,
Body-Malapel M, Inohara N, Nunez G: RICK/RIP2 mediates
innate immune responses induced through Nod1 and Nod2
but not TLRs. J Immunol 2007, 178:2380-2386.
100. Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA:
NOD2 pathway activation by MDP or Mycobacterium tubercu-
losis infection involves the stable polyubiquitination of Rip2. J
Biol Chem 2007, 282:36223-36229.
101. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR,
Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ, Philpott DJ:
CARD4/Nod1 mediates NF-kappaB and JNK activation by
invasive Shigella flexneri. EMBO Rep 2001, 2:736-742.
102. Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ: Invasive Shigella
flexneri activates NF-kappa B through a lipopolysaccharide-
dependent innate intracellular response and leads to IL-8
expression in epithelial cells. J Immunol 2000, 165:903-914.
103. Kim JG, Lee SJ, Kagnoff MF: Nod1 is an essential signal trans-
ducer in intestinal epithelial cells infected with bacteria that
avoid recognition by toll-like receptors. Infect Immun 2004, 72:
1487-1495.
104. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP,
Athman R, Mémet S, Huerre MR, Coyle AJ, DiStefano PS, San-
sonetti PJ, Labigne A, Bertin J, Philpott DJ, Ferrero RL: Nod1
responds to peptidoglycan delivered by the Helicobacter
pylori cag pathogenicity island. Nat Immunol 2004, 5:1166-
1174.
105. Fischer W, Puls J, Buhrdorf R, Gebert B, Odenbreit S, Haas R:
Systematic mutagenesis of the Helicobacter pylori cag patho-
genicity island: essential genes for CagA translocation in host
cells and induction of interleukin-8. Mol Microbiol 2001, 42:
1337-1348.
106. Cascales E, Christie PJ: The versatile bacterial type IV secre-
tion systems. Nat Rev Microbiol 2003, 1:137-149.
107. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach W,
Sahly H, Lucius R, Fölsch UR, Philpott D, Schreiber S: Influence
of polymorphisms in the NOD1/CARD4 and NOD2/CARD15
genes on the clinical outcome of Helicobacter pylori infection.
Cell Microbiol 2006, 8:1188-1198.
108. Zilbauer M, Dorrell N, Elmi A, Lindley KJ, Schuller S, Jones HE,
Klein NJ, Nunez G, Wren BW, Bajaj-Elliott M: A major role for
intestinal epithelial nucleotide oligomerization domain 1
(NOD1) in eliciting host bactericidal immune responses to
Campylobacter jejuni. Cell Microbiol 2007, 9:2404-2416.
109. Travassos LH, Carneiro LA, Girardin SE, Boneca IG, Lemos R,
Bozza MT, Domingues RC, Coyle AJ, Bertin J, Philpott DJ,
Plotkowski MC: Nod1 participates in the innate immune
response to Pseudomonas aeruginosa. J Biol Chem 2005,
280:36714-36718.
110. Welter-Stahl L, Ojcius DM, Viala J, Girardin S, Liu W, Delarbre C,
Philpott D, Kelly KA, Darville T: Stimulation of the cytosolic
receptor for peptidoglycan, Nod1, by infection with Chlamydia
trachomatis or Chlamydia muridarum. Cell Microbiol 2006, 8:
1047-1057.
111. Laitinen T, Daly MJ, Rioux JD, Kauppi P, Laprise C, Petäys T,
Green T, Cargill M, Haahtela T, Lander ES, Laitinen LA, Hudson
TJ, Kere J: A susceptibility locus for asthma-related traits on
chromosome 7 revealed by genome-wide scan in a founder
population. Nat Genet 2001, 28:87-91.
112. Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Novak N, Bau-
recht HJ, Groer W, Darsow U, Heinrich J, Gauger A, Schafer T,
Jakob T, Behrendt H, Wichmann HE, Ring J, Illig T: Association
of NOD1 polymorphisms with atopic eczema and related phe-
notypes. J Allergy Clin Immunol 2005, 116:177-184.
113. Zouali H, Lesage S, Merlin F, Cézard JP, Colombel JF, Belaiche J,
Almer S, Tysk C, O’Morain C, Gassull M, Christensen S, Finkel Y,
Modigliani R, Gower-Rousseau C, Macry J, Chamaillard M,
Thomas G, Hugot JP; EPWG group; EPIMAD group: CARD4/
NOD1 is not involved in inflammatory bowel disease. Gut
2003, 52:71-74.
114. Van Limbergen J, Nimmo ER, Russell RK, Drummond HE, Smith L,
Anderson NH, Davies G, Arnott ID, Wilson DC, Satsangi J: Inves-
tigation of NOD1/CARD4 variation in inflammatory bowel
disease using a haplotype-tagging strategy. Hum Mol Genet
2007, 16:2175-2186.
115. Tremelling M, Hancock L, Bredin F, Sharpstone D, Bingham SA,
Parkes M: Complex insertion/deletion polymorphism in NOD1
(CARD4) is not associated with inflammatory bowel disease
susceptibility in East Anglia panel. Inflamm Bowel Dis 2006,
12:967-971.
116. Coto-Segura P, Mallo-Garcia S, Costa-Romero M, Arostegui JI,
Yague J, Ramos-Polo E, Santos-Juanes J: A sporadic case of
early-onset sarcoidosis resembling Blau syndrome due to the
recurrent R334W missense mutation on the NOD2 gene. Br J
Dermatol 2007, 157:1257-1259.
117. Kanazawa N, Matsushima S, Kambe N, Tachibana T, Nagai S,
Miyachi Y: Presence of a sporadic case of systemic granulo-
matosis syndrome with a CARD15 mutation. J Invest Dermatol
2004, 122:851-852.
118. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R,
Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR,
Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH: A
frameshift mutation in NOD2 associated with susceptibility to
Crohn’s disease. Nature 2001, 411:603-606.
119. Romagnani P, Annunziato F, Baccari MC, Parronchi P: T cells
and cytokines in Crohn’s disease. Curr Opin Immunol 1997, 9:
793-799.
120. Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S,
Tysk C, O’Morain C, Gassull M, Binder V, Finkel Y, Modigliani R,
Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot AS,
Thomas G, Hugot JP; EPWG-IBD Group; EPIMAD Group;
GETAID Group: CARD15/NOD2 mutational analysis and geno-
type-phenotype correlation in 612 patients with inflammatory
bowel disease. Am J Hum Genet 2002, 70:845-857.
121. Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T,
Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nuñez G:
Crohn’s disease-associated NOD2 variants share a signaling
defect in response to lipopolysaccharide and peptidoglycan.
Gastroenterology 2003, 124:140-146.
122. Netea MG, Ferwerda G, de Jong DJ, Girardin SE, Kullberg BJ, van
der Meer JW: NOD2 3020insC mutation and the pathogenesis
of Crohn’s disease: impaired IL-1beta production points to a
loss-of-function phenotype. Neth J Med 2005, 63:305-308.
123. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D: Role of inter-
leukin 1 in inflammatory bowel disease: enhanced production
during active disease. Gut 1990, 31:686-689.
124. Mitsuyama K, Sata M, Tanikawa K: Significance of interleukin-6
in patients with inflammatory bowel disease. Gastroenterol Jpn
1991, 26:20-28.
125. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O,
Luzza F, Pallone F: Interleukin 12 is expressed and actively
released by Crohn’s disease intestinal lamina propria
mononuclear cells. Gastroenterology 1997, 112:1169-1178.
126. Watanabe T, Kitani A, Murray PJ, Strober W: NOD2 is a negative
Arthritis Research & Therapy    Vol 10 No 6 Mathews et al.
Page 12 of 14
(page number not for citation purposes)
regulator of Toll-like receptor 2-mediated T helper type 1
responses. Nat Immunol 2004, 5:800-808.
127. Watanabe T, Kitani A, Murray PJ, Wakatsuki Y, Fuss IJ, Strober
W: Nucleotide binding oligomerization domain 2 deficiency
leads to dysregulated TLR2 signaling and induction of
antigen-specific colitis. Immunity 2006, 25:473-485.
128. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G:
The effect of NOD2 activation on TLR2-mediated cytokine
responses is dependent on activation dose and NOD2 geno-
type. Genes Immun 2008, 9:274-278.
129. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N,
Nunez G, Flavell RA: Nod2-dependent regulation of innate and
adaptive immunity in the intestinal tract. Science 2005, 307:
731-734.
130. Ouellette AJ, Bevins CL: Paneth cell defensins and innate
immunity of the small bowel. Inflamm Bowel Dis 2001, 7:43-
50.
131. Ayabe T, Satchell DP, Wilson CL, Parks WC, Selsted ME, Ouel-
lette AJ: Secretion of microbicidal alpha-defensins by intesti-
nal Paneth cells in response to bacteria. Nat Immunol 2000, 1:
113-118.
132. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FF, Zimmer-
mann E, Tretiakova M, Cho JH, Hart J, Greenson JK, Keshav S,
Nuñez G: Expression of NOD2 in Paneth cells: a possible link
to Crohn’s ileitis. Gut 2003, 52:1591-1597.
133. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher
PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber
S, Lewis CM, Mathew CG: The contribution of NOD2 gene
mutations to the risk and site of disease in inflammatory
bowel disease. Gastroenterology 2002, 122:867-874.
134. Hampe J, Frenzel H, Mirza MM, Croucher PJ, Cuthbert A,
Mascheretti S, Huse K, Platzer M, Bridger S, Meyer B, Nürnberg
P, Stokkers P, Krawczak M, Mathew CG, Curran M, Schreiber S:
Evidence for a NOD2-independent susceptibility locus for
inflammatory bowel disease on chromosome 16p. Proc Natl
Acad Sci USA 2002, 99:321-326.
135. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M,
Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feath-
ers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF,
Bevins CL: Reduced Paneth cell alpha-defensins in ileal
Crohn’s disease. Proc Natl Acad Sci USA 2005, 102:18129-
18134.
136. Kramer M, Netea MG, de Jong DJ, Kullberg BJ, Adema GJ:
Impaired dendritic cell function in Crohn’s disease patients
with NOD2 3020insC mutation. J Leukoc Biol 2006, 79:860-
866.
137. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K,
Albrecht M, Mayr G, De La Vega FM, Briggs J, Günther S,
Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer
T, Platzer M, Mathew CG, Krawczak M, Schreiber S: A genome-
wide association scan of nonsynonymous SNPs identifies a
susceptibility variant for Crohn disease in ATG16L1. Nat Genet
2007, 39:207-211.
138. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA,
Fisher SA, Roberts RG, Nimmo ER, Cummings FR, Soars D,
Drummond H, Lees CW, Khawaja SA, Bagnall R, Burke DA, Tod-
hunter CE, Ahmad T, Onnie CM, McArdle W, Strachan D, Bethel
G, Bryan C, Lewis CM, Deloukas P, Forbes A, Sanderson J, Jewell
DP, Satsangi J, Mansfield JC; Wellcome Trust Case Control Con-
sortium, et al.: Sequence variants in the autophagy gene IRGM
and multiple other replicating loci contribute to Crohn’s
disease susceptibility. Nat Genet 2007, 39:830-832.
139. Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R,
Keniry A, Nimmo ER, Drummond H, Onnie CM, Prescott NJ,
Sanderson J, Bredin F, Berzuini C, Forbes A, Lewis CM, Cardon
L, Deloukas P, Jewell D, Mathew CG, Parkes M, Satsangi J: IL23R
variation determines susceptibility but not disease phenotype
in inflammatory bowel disease. Gastroenterology 2007, 132:
1657-1664.
140. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y,
Inohara N, Núñez G, Kishi Y, Koike Y, Shimosegawa T, Shi-
moyama T, Hibi T: Lack of common NOD2 variants in Japanese
patients with Crohn’s disease. Gastroenterology 2002, 123:86-
91.
141. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y:
Absence of mutation in the NOD2/CARD15 gene among 483
Japanese patients with Crohn’s disease. J Hum Genet 2002,
47:469-472.
142. McGovern DP, Van Heel DA, Negoro K, Ahmad T, Jewell DP:
Further evidence of IBD5/CARD15 (NOD2) epistasis in the
susceptibility to ulcerative colitis. Am J Hum Genet 2003, 73:
1465-1466.
143. Manouvrier-Hanu S, Puech B, Piette F, Boute-Benejean O, Des-
bonnet A, Duquesnoy B, Farriaux JP: Blau syndrome of granulo-
matous arthritis, iritis, and skin rash: a new family and review
of the literature. Am J Med Genet 1998, 76:217-221.
144. van Duist MM, Albrecht M, Podswiadek M, Giachino D, Lengauer
T, Punzi L, De Marchi M: A new CARD15 mutation in Blau syn-
drome. Eur J Hum Genet 2005, 13:742-747.
145. Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S,
Chareyre F, Bui TH, Giovannini M, Zaehringer U, Penard-
Lacronique V, Sansonetti PJ, Hugot JP, Thomas G: Gene-envi-
ronment interaction modulated by allelic heterogeneity in
inflammatory diseases. Proc Natl Acad Sci USA 2003, 100:
3455-3460.
146. Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume
M, Nagai S, Fuji A, Yuasa T, Manki A, Sakurai Y, Nakajima M,
Kobayashi H, Fujiwara I, Tsutsumi H, Utani A, Nishigori C, Heike T,
Nakahata T, Miyachi Y: Early-onset sarcoidosis and CARD15
mutations with constitutive nuclear factor-kappaB activation:
common genetic etiology with Blau syndrome. Blood 2005,
105:1195-1197.
147. Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J,
Schwinger E, Schreiber S: CARD15 gene mutations in sar-
coidosis. Eur Respir J 2003, 22:748-754.
148. Newman B, Rubin LA, Siminovitch KA: NOD2/CARD15 gene
mutation is not associated with susceptibility to Wegener’s
granulomatosis. J Rheumatol 2003, 30:305-307.
149. Brenmoehl J, Herfarth H, Glück T, Audebert F, Barlage S, Schmitz
G, Froehlich D, Schreiber S, Hampe J, Schölmerich J, Holler E,
Rogler G: Genetic variants in the NOD2/CARD15 gene are
associated with early mortality in sepsis patients. Intensive
Care Med 2007, 33:1541-1548.
150. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J,
Eissner G, Scholmerich J, Andreesen R: Both donor and recipi-
ent NOD2/CARD15 mutations associate with transplant-
related mortality and GvHD following allogeneic stem cell
transplantation. Blood 2004, 104:889-894.
151. Joosten LA, Heinhuis B, Abdollahi-Roodsaz S, Ferwerda G,
Lebourhis L, Philpott DJ, Nahori MA, Popa C, Morre SA, van der
Meer JW, Girardin SE, Netea MG, van den Berg WB: Differential
function of the NACHT-LRR (NLR) members Nod1 and Nod2
in arthritis. Proc Natl Acad Sci USA 2008, 105:9017-9022.
152. Pawlik A, Kurzawski M, Gawronska-Szklarz B, Drozdzik M, Her-
czynska M: NOD2 allele variants in patients with rheumatoid
arthritis. Clin Rheumatol 2007, 26:868-871.
153. Cummings J, Cooney R, Clarke G, Beckley J, Geremia A, Cardon
L, Jewell D: The genetics of Nod-like receptors proteins in
Crohn’s disease. J Crohn’s Colitis 2008, 2:P191.
154. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD,
Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Das-
sopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha
MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan
SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C,
Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, et al.: Genome-
wide association defines more than 30 distinct susceptibility
loci for Crohn’s disease. Nat Genet 2008, 40:955-962.
155. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB,
Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody
KL, Schaible TF, Van Deventer SJ: Efficacy and safety of retreat-
ment with anti-tumor necrosis factor antibody (infliximab) to
maintain remission in Crohn’s disease. Gastroenterology 1999,
117:761-769.
156. Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schu-
bert S, Olson A, Bao W, Folsch UR, Schreiber S: Response to
infliximab treatment in Crohn’s disease is not associated with
mutations in the CARD15 (NOD2) gene: an analysis in 534
patients from two multicenter, prospective GCP-level trials.
Pharmacogenetics 2002, 12:509-515.
157. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A,
Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R,
Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian
Group of Infliximab Expanded Access Program and Fondation
Jean Dausset CEPH, Paris, France: NOD2/CARD15 does not
Available online http://arthritis-research.com/content/10/6/228
Page 13 of 14
(page number not for citation purposes)
influence response to infliximab in Crohn’s disease. Gastroen-
terology 2002, 123:106-111.
158. Carter JD, Valeriano J, Vasey FB: Crohn disease worsened by
anakinra administration. J Clin Rheumatol 2003, 9:276-277.
159. Milman N, Andersen CB, Hansen A, van Overeem Hansen T,
Nielsen FC, Fledelius H, Ahrens P, Nielsen OH: Favourable
effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in
monozygotic twins with a de novo CARD15 mutation. APMIS
2006, 114:912-919.
160. Aróstegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M,
Moreno P, García-Consuegra J, Naranjo A, Ramos E, de Paz P,
Rius J, Plaza S, Yagüe J: NOD2 gene-associated pediatric gran-
ulomatous arthritis: clinical diversity, novel and recurrent
mutations, and evidence of clinical improvement with inter-
leukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007,
56:3805-3813.
161. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, van der Ven J,
Kullberg BJ, Netea MG, van der Meer JW: Crystals of monosodium
urate monohydrate enhance LPS-induced release of interleukin-
1β by mononuclear cells through a caspase-1 mediated
process. Ann Rheum Dis 2008 [Epub ahead of print].
162. Uehara A, Iwashiro A, Sato T, Yokota S, Takada H: Antibodies to
proteinase 3 prime human monocytic cells via protease-acti-
vated receptor-2 and NF-kappaB for Toll-like receptor- and
NOD-dependent activation. Mol Immunol 2007, 44:3552-3562.
163. Uehara A, Hirabayashi Y, Takada H: Antibodies to proteinase 3
(PR3-ANCA) prime human oral, lung, and kidney epithelial
cells through protease-activated receptor-2 to secrete proin-
flammatory cytokines upon stimulation with agonists to
various Toll-like receptors, NOD1 and NOD2. Clin Vaccine
Immunol 2008, 15:1060-1066.
164. Matsumoto T, Kaneko T, Seto M, Wada H, Kobayashi T, Nakatani
K, Tonomura H, Tono Y, Ohyabu M, Nobori T, Shiku H, Sudo A,
Uchida A, Kurosawa DJ, Kurosawa S: The membrane pro-
teinase 3 expression on neutrophils was downregulated after
treatment with infliximab in patients with rheumatoid arthritis.
Clin Appl Thromb Hemost 2008, 14:186-192.
165. Bhat A, Naguwa SM, Gershwin ME: Genetics and new treat-
ment modalities for familial Mediterranean fever. Ann N Y
Acad Sci 2007, 1110:201-208.
166. Calligaris L, Marchetti F, Tommasini A, Ventura A: The efficacy of
anakinra in an adolescent with colchicine-resistant familial
Mediterranean fever. Eur J Pediatr 2008, 167:695-696.
167. Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ,
Kastner DL: The B30.2 domain of pyrin, the familial Mediter-
ranean fever protein, interacts directly with caspase-1 to mod-
ulate IL-1beta production. Proc Natl Acad Sci USA 2006,
103:9982-9987.
168. Roldan R, Ruiz AM, Miranda MD, Collantes E: Anakinra: new
therapeutic approach in children with Familial Mediterranean
Fever resistant to colchicine. Joint Bone Spine 2008, 75:504-
505
169. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W,
Mejias A, Ardura M, Chung W, Wise C, Palucka K, Ramilo O,
Punaro M, Banchereau J, Pascual V: Blood leukocyte microar-
rays to diagnose systemic onset juvenile idiopathic arthritis
and follow the response to IL-1 blockade. J Exp Med 2007,
204:2131-2144.
170. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ: Anakinra for
flares of pyogenic arthritis in PAPA syndrome. Rheumatology
(Oxford) 2005, 44:406-408.
171. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A:
Effect of etanercept and anakinra on inflammatory attacks in
the hyper-IgD syndrome: introducing a vaccination provoca-
tion model. Neth J Med 2005, 63:260-264.
172. Benezra D, Maftzir G, Barak V: Blood serum interleukin-1
receptor antagonist in pars planitis and ocular Behcet
disease. Am J Ophthalmol 1997, 123:593-598.
173. Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT: Cytokine
inhibitors: soluble tumor necrosis factor receptor 1 and inter-
leukin-1 receptor antagonist in Behcet’s disease. Rheumatol
Int 2005, 25:1-5.
174. Imrie FR, Dick AD: Biologics in the treatment of uveitis. Curr
Opin Ophthalmol 2007, 18:481-486.
175. Carneiro LA, Travassos LH, Girardin SE: Nod-like receptors in
innate immunity and inflammatory diseases. Ann Med 2007,
39:581-593.
Arthritis Research & Therapy    Vol 10 No 6 Mathews et al.
Page 14 of 14
(page number not for citation purposes)
